» Articles » PMID: 37107312

Attention-Deficit/Hyperactivity Disorder Animal Model Presents Retinal Alterations and Methylphenidate Has a Differential Effect in ADHD Versus Control Conditions

Overview
Date 2023 Apr 28
PMID 37107312
Authors
Affiliations
Soon will be listed here.
Abstract

Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most prevalent neurodevelopmental disorders. Interestingly, children with ADHD seem to experience more ophthalmologic abnormalities, and the impact of methylphenidate (MPH) use on retinal physiology remains unclear. Thus, we aimed to unravel the retina's structural, functional, and cellular alterations and the impact of MPH in ADHD versus the control conditions. For that, spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) were used as animal models of ADHD and the controls, respectively. Animals were divided into four experimental groups as follows: WKY vehicle (Veh; tap water), WKY MPH (1.5 mg/kg/day), SHR Veh, SHR MPH. Individual administration was performed by gavage between P28-P55. Retinal physiology and structure were evaluated at P56 followed by tissue collection and analysis. The ADHD animal model presents the retinal structural, functional, and neuronal deficits, as well as the microglial reactivity, astrogliosis, blood-retinal barrier (BRB) hyperpermeability and a pro-inflammatory status. In this model, MPH had a beneficial effect on reducing microgliosis, BRB dysfunction, and inflammatory response, but did not correct the neuronal and functional alterations in the retina. Curiously, in the control animals, MPH showed an opposite effect since it impaired the retinal function, neuronal cells, and BRB integrity, and also promoted both microglia reactivity and upregulation of pro-inflammatory mediators. This study unveils the retinal alterations in ADHD and the opposite effects induced by MPH in the retina of ADHD and the control animal models.

Citing Articles

Changes in Cortisol and in Oxidative/Nitrosative Stress Indicators after ADHD Treatment.

Garre-Morata L, Haro T, Villen R, Fernandez-Lopez M, Escames G, Molina-Carballo A Antioxidants (Basel). 2024; 13(1).

PMID: 38247516 PMC: 10812591. DOI: 10.3390/antiox13010092.


P2X4 signalling contributes to hyperactivity but not pain sensitization comorbidity in a mouse model of attention deficit/hyperactivity disorder.

Bou Sader Nehme S, Sanchez-Sarasua S, Adel R, Tuifua M, Ali A, Essawy A Front Pharmacol. 2024; 14:1288994.

PMID: 38239187 PMC: 10794506. DOI: 10.3389/fphar.2023.1288994.

References
1.
Martins T, Burgoyne T, Kenny B, Hudson N, Futter C, Ambrosio A . Methamphetamine-induced nitric oxide promotes vesicular transport in blood-brain barrier endothelial cells. Neuropharmacology. 2012; 65:74-82. PMC: 3546162. DOI: 10.1016/j.neuropharm.2012.08.021. View

2.
London A, Benhar I, Schwartz M . The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2012; 9(1):44-53. DOI: 10.1038/nrneurol.2012.227. View

3.
Volkow N, Wang G, Kollins S, Wigal T, Newcorn J, Telang F . Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009; 302(10):1084-91. PMC: 2958516. DOI: 10.1001/jama.2009.1308. View

4.
Marrocco E, Indrieri A, Esposito F, Tarallo V, Carboncino A, Alvino F . α-synuclein overexpression in the retina leads to vision impairment and degeneration of dopaminergic amacrine cells. Sci Rep. 2020; 10(1):9619. PMC: 7295803. DOI: 10.1038/s41598-020-66497-6. View

5.
Boia R, Dias P, Galindo-Romero C, Ferreira H, Aires I, Vidal-Sanz M . Intraocular implants loaded with AR agonist rescue retinal ganglion cells from ischemic damage. J Control Release. 2022; 343:469-481. DOI: 10.1016/j.jconrel.2022.02.001. View